PEP Health Unveils the First Real-Time Trust Score for U.S. Healthcare
MINNEAPOLIS, April 29, 2025 /PRNewswire/ - PEP Health, the AI-powered patient experience platform trusted by leading hospitals, payers, and health systems, today announced the launch of its Trust Score, the first real-time, validated metric that quantifies how patients experience and express trust in healthcare.
Built from millions of unsolicited patient narratives and developed alongside a leading U.S. health system, the Trust Score brings long-missing measurement, visibility, and actionability to one of the most critical drivers of health outcomes: patient trust.
Download PEP Health's Trust white paper here.
'In healthcare, trust isn't abstract. It directly impacts outcomes, adherence, and loyalty,' said Dr. Mark Lomax, CEO of PEP Health. 'For the first time, hospitals, payers, and providers can measure trust in real time, pinpoint when and where it erodes, and take immediate steps to rebuild it.'
The Trust Score is already being piloted nationwide, including at ECU Health, a rural health system committed to human-centered care.
'Trust is the foundation of the relationship between healthcare and those they serve. When trust is present in the relationship, patients adhere to treatment plans, seek medical care when needed, and have frank conversations with their care team which is vital to their health planning,' said Dr. Julie Kennedy Oehlert, Chief Experience Officer at ECU Health. 'This trust also fuels the passion and purpose of those that provide care, insulating against burnout.'
More Than a Feeling: Why Trust Now Has a Score
While traditional surveys often struggle with delays, low response rates, and limited reach, PEP Health's Trust Score draws from the real, unprompted voices of patients, capturing their experiences across social media platforms, review sites, and forums. Using advanced machine learning and healthcare-specific natural language processing (NLP) technology, PEP Health analyzes this data into structured insights that reflect the full spectrum of patient experience.
At the core of the Trust Score are Drivers of Trust (such as caring, kindness, effective listening) and Indicators of Trust (such as patient retention and health outcomes)
PEP Health's patient experience insights are validated against national benchmarks including HCAHPS and insurer quality metrics and highlighted in peer-reviewed research published in BMJ Quality & Safety and The Lancet (read more here ).
A Strategic Metric for Today's Healthcare Leaders
Trust is no longer just a value statement: it directly affects health equity, financial performance, and community engagement. Internal PEP Health data shows that a one-point decline in patient satisfaction can result in more than $12 million in annual lost revenue for a large health system.
With the Trust Score, healthcare leaders can now:
'For too long, others have defined what trust should look like in healthcare,' continued Dr. Lomax. 'It's time to listen to patients themselves. When trust breaks down, patients don't show up, don't open up, and don't follow through. Now, for the first time, we can measure trust and take meaningful action to rebuild it.'
Early Access and White Paper
Healthcare leaders can now download PEP Health's new white paper and apply for early access to the Trust Score platform by completing the Early Access request form.
About PEP Health
PEP Health's advanced AI uses healthcare-specific natural language processing (NLP) and machine learning to analyze diverse, unsolicited patient feedback from online sources such as social media, review platforms, and forums, alongside hospital surveys and internal data. By providing a comprehensive, real-time view of patient and community experiences, PEP Health helps healthcare providers gain insights that traditional surveys often miss. This approach enables organizations to understand patient preferences more deeply, focus on what matters most, and align care with evolving expectations.
To learn more, please visit www.pephealth.ai
View original content: https://www.prnewswire.com/news-releases/pep-health-unveils-the-first-real-time-trust-score-for-us-healthcare-302440219.html
SOURCE PEP Health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Glaucoma Treatment Devices Market Set to Surge from USD 4.5 Billion in 2024 to USD 7.2 Billion by 2033, Driven by Advancements in Minimally Invasive Surgical Technologies: Market Research Intellect
The growth of the Glaucoma Treatment Devices Market is primarily driven by the rising global prevalence of glaucoma, increasing awareness about early diagnosis, and advancements in minimally invasive treatment options. Technological innovations in surgical devices, coupled with supportive government initiatives and healthcare infrastructure improvements, are expected to accelerate adoption and significantly contribute to the market's steady growth over the forecast period. LEWES, Del., July 31, 2025 /PRNewswire/ -- The Glaucoma Treatment Devices Market was valued at approximately USD 4.5 billion in 2024 and is projected to reach USD 7.2 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of 6.5% from 2026 to 2033. This growth is attributed to the rising burden of glaucoma worldwide, increasing adoption of advanced surgical interventions, and improved accessibility to ophthalmic care. Expanding healthcare infrastructure and ongoing innovation in treatment technologies are further enhancing market size and investment potential. Key Highlights of the Report: The global Glaucoma Treatment Devices Market reached USD 4.5 billion in 2024 and is anticipated to grow to USD 7.2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Technological advancements in minimally invasive glaucoma surgery (MIGS) devices are accelerating adoption across hospitals and specialty clinics. Aging populations and increasing glaucoma diagnoses are significantly boosting demand for long-term treatment solutions. North America continues to dominate the market, while Asia-Pacific is projected to witness the fastest growth due to rising healthcare investment. Leading market players are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their global footprint. Why This Report Matters: This report offers a comprehensive analysis of the Glaucoma Treatment Devices Market, delivering valuable insights into market size, growth trends, and key drivers shaping the industry through 2033. It equips stakeholders, investors, and healthcare professionals with data-driven intelligence to make informed decisions. By examining regional dynamics, competitive strategies, and technological advancements, the report highlights growth opportunities and emerging risks. Whether for market entry or expansion planning, this research provides critical knowledge to navigate a rapidly evolving ophthalmic device landscape. Who Should Read This Report: Medical Device Manufacturers: To identify innovation trends and growth areas in glaucoma treatment technologies. Healthcare Providers & Ophthalmologists: To understand device adoption trends and treatment advancements. Hospital Procurement Teams: To evaluate top-performing products and make strategic purchasing decisions. Investors & Analysts: To assess market opportunities, ROI potential, and emerging investment segments. Pharmaceutical & Biotech Firms: To explore partnerships and product development aligned with surgical treatments. Regulatory Bodies & Policymakers: To track industry developments and ensure compliance with evolving standards. For more information or to purchase the report, please contact us at: Browse in-depth TOC on "Global Glaucoma Treatment Devices Market Size" 202 - Pages126 – Tables37 – Figures Global Glaucoma Treatment Devices Market Overview Market Driver 1. Rising Prevalence of Glaucoma Globally The global rise in aging populations has significantly contributed to the increase in glaucoma cases, especially in regions such as North America, Europe, and Asia-Pacific. Glaucoma remains a leading cause of irreversible blindness, and the growing awareness campaigns are facilitating early diagnosis and treatment. Primary open-angle glaucoma and angle-closure glaucoma are among the most prevalent types, driving higher demand for surgical intervention devices. Emerging economies are showing rapid uptake of eye health services due to improving healthcare infrastructure and government initiatives. Public health organizations and non-profits are working towards large-scale screening and education programs to reduce disease burden. 2. Technological Advancements in Glaucoma Devices Innovations in minimally invasive glaucoma surgery (MIGS) devices are transforming patient outcomes and reducing recovery times. Smart implantable devices capable of monitoring intraocular pressure (IOP) in real time are gaining clinical interest. Advancements in laser-based procedures and micro-stent technologies offer less invasive and more effective alternatives to traditional surgeries. The integration of AI and IoT with ophthalmic devices is expected to further revolutionize glaucoma management. Research and development investment from leading players continues to push the boundaries of device precision and safety. 3. Increasing Demand for Minimally Invasive Surgery (MIGS) MIGS procedures offer quicker recovery, fewer complications, and long-term management solutions for mild to moderate glaucoma. Hospitals and eye clinics are adopting MIGS as a frontline treatment, especially in patients unresponsive to medication. Surgeons prefer MIGS due to the reduced learning curve and increased safety profile compared to traditional surgeries. The growing body of clinical evidence supporting the efficacy of MIGS is accelerating its adoption globally. Medical device companies are focusing on developing next-generation MIGS implants tailored to patient-specific anatomical needs. To Purchase a Comprehensive Report Analysis: Market Restraint 1. High Cost and Limited Reimbursement Advanced glaucoma treatment devices, especially MIGS and smart implants, are often expensive and unaffordable for many patients. In low- and middle-income regions, lack of insurance coverage and weak reimbursement structures make access more difficult. Hospitals may be hesitant to invest in high-cost surgical equipment without clear financial incentives or ROI. Cost-related barriers discourage widespread adoption, even in regions where clinical need is high. 2. Regulatory and Operational Barriers Varying global regulatory standards can delay the introduction of new glaucoma devices into certain markets. Approval processes can be lengthy and costly, impacting smaller device manufacturers disproportionately. A shortage of trained ophthalmic surgeons familiar with advanced techniques limits the practical use of new devices. Operational challenges like poor device availability and long procurement cycles hinder adoption in developing areas. 3. Low Awareness and Poor Patient Compliance Lack of public knowledge about glaucoma symptoms and risks leads to delayed diagnosis and missed treatment windows. In rural or underserved regions, patients often lack access to routine eye exams or follow-up care. Even after surgery, poor adherence to post-operative monitoring and care reduces long-term treatment success. Educational and awareness gaps limit both prevention and management, especially in high-risk demographics. Geographical Dominance: North America holds a dominant position in the Glaucoma Treatment Devices Market, driven by advanced healthcare infrastructure, high awareness levels, and strong adoption of minimally invasive surgical technologies. The region benefits from a robust network of ophthalmic specialists and early access to regulatory-approved innovations. Meanwhile, Europe follows closely, supported by favorable reimbursement frameworks and a growing elderly population. Asia-Pacific is projected to experience the fastest growth due to rising glaucoma prevalence, expanding healthcare access, and increased investment in ophthalmic care across countries like China, India, and Japan. Key Players Leading companies are actively shaping the future of the Glaucoma Treatment Devices Market through innovation, strategic expansion, and product development. Key players include Alcon Inc., Glaukos Corporation, Ivantis Inc. (a part of Alcon), New World Medical, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Vision, Ellex Medical Lasers Ltd., AqueSys Inc., Lumenis Ltd., and Sight Sciences, Inc. Glaucoma Treatment Devices Market Segment Analysis Based on the research, Market Research Intellect has segmented the global market into Technology, Application, Component and Geography. Glaucoma Treatment Devices Market by Device Type Diagnostic Devices Surgical Devices Therapeutic Devices Monitoring Devices Glaucoma Treatment Devices Market by End User Hospitals Eye Clinics Home Care Settings Research Institutions Glaucoma Treatment Devices Market, by Product Type Intraocular Pressure (IOP) Lowering Devices Laser Treatment Devices Drainage Devices Ocular Implants Glaucoma Treatment Devices Market, by Geography North America U.S Canada Mexico Europe Germany France U.K Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific ROW Middle East & Africa Latin America Browse Related Reports: Open Angle Glaucoma Therapeutics Market is categorized based on Drug Type (Prostaglandin Analogs, Beta-Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Route of Administration (Oral, Topical, Injectable) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Patient Type (Adult, Pediatric) and Formulation (Liquid, Tablet, Sustained Release) and geographical regions Anti Glaucoma Eyedrops Market is categorized based on Prostaglandin Analogues (Latanoprost, Bimatoprost, Travoprost, Unoprostone, Tafluprost) and Beta Blockers (Timolol, Betaxolol, Carteolol, Levobunolol, Metipranolol) and Alpha Agonists (Brimonidine, Apraclonidine, Dipivefrin, Clonidine, Oxymetazoline) and Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide, Brominidine) and Rho Kinase Inhibitors (Netarsudil, Ripasudil, Y-27632, AR-13324, K-115) and geographical regions Glaucoma Medications Market is categorized based on Medication Type (Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Formulation Type (Eye Drops, Oral Medications, Surgical Treatments, Laser Treatments, Implants) and Administration Route (Topical, Systemic, Intravitreal, Surgical, Ocular Insert) and geographical regions Glaucoma Pharmaceutical Market is categorized based on Therapeutic Class (Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Drug Formulation (Topical, Oral, Injectable, Sustained-release, Combination Therapy) and Route of Administration (Ophthalmic, Systemic, Intravitreal, Subconjunctival, Transdermal) and geographical regions About Us: Market Research Intellect Welcome to Market Research Intellect, where we lead the way in global research and consulting, proudly serving over 5,000 esteemed clients worldwide. Our mission is to empower your business with cutting-edge analytical research solutions, delivering comprehensive, information-rich studies that are pivotal for strategic growth and critical revenue decisions. Unmatched Expertise: Our formidable team of 250 highly skilled analysts and subject matter experts (SMEs) is the backbone of our operations. With extensive training in advanced data collection and governance, we delve into over 25,000 high-impact and niche markets. Our experts seamlessly integrate modern data collection techniques, robust research methodologies, and collective industry experience o produce precise, insightful, and actionable research. Diverse Industry Coverage: We cater to a wide array of industries, ensuring that our insights are both relevant and specialized. Our expertise spans: Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages Having collaborated with numerous Fortune 2000 companies, we bring unparalleled experience and reliability to meet all your research needs. Our proven track record reflects our commitment to excellence and client satisfaction. Contact Us: Mr. Edwyne FernandesMarket Research IntellectCall Us on: +1 743 222 5439Email: sales@ Logo: View original content: SOURCE Market Research Intellect Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation TOKYO and CAMBRIDGE, Mass., July 30, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SC-AI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways— targeting both protofibrils and plaque, which can impact tau accumulation downstream. Importance of Ongoing Treatment and SC Development Program Due to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so patients can continue to fight this progressive, relentless disease. Clinical trials of lecanemab SC were conducted as a sub-study of the open-label extension (OLE) following the core Phase 3 Clarity AD study in individuals with early AD, to evaluate a range of doses administered by SC vial or autoinjector. Eisai has developed a SC-AI for maintenance therapy at a dose of 360 mg weekly and a 500 mg SC-AI is being developed for initiation dosing. Similar Impact on Clinical Outcomes and Biomarkers with IV and SC Dosing The pharmacology (PK/PD), clinical (efficacy endpoints such as CDR-SB) and biomarker (amyloid PET and blood biomarkers) relationships established with extensive clinical data supported the FDA approval of IV maintenance therapy after the initial 18 months of treatment and support the investigational SC maintenance dose option. Data supports that transitioning to a weekly 360 mg SC AI dose of lecanemab after 18 months of initiation dose (10 mg/kg IV biweekly) maintains clinical and biomarker benefits comparable to continued biweekly IV dosing. Clinical and biomarker responses at 48 months with monthly IV maintenance dosing are similar to the responses with ongoing biweekly dosing whether patients are amyloid positive (>30 CL) or negative (<30 CL) at 18 months. Data shows the 500 mg SC AI has equivalent exposure as the initial treatment regimen of 10 mg/kg IV biweekly up to 18 months for amyloid removal, efficacy, and ARIA-E. Safety MattersThe safety profile of 360 mg weekly SC maintenance dosing was shown to be consistent with that of IV maintenance therapy, with <1% systemic injection/infusion reactions. Across all SC doses, the rate of systemic injection/infusion reactions is 1% compared to 26% with IV. The 360 mg SC maintenance dose was initiated after 18 months of IV treatment, beyond the high-risk period for ARIA. There were 0 cases of ARIA-E observed out of 49 treated with 360 mg SC weekly maintenance for a mean of 6 months. Study Participants Successfully Administered SC-AI and Found it Easy to UseTo optimize the safe and effective use of SC autoinjector (SC-AI), additional studies were conducted, including a human factors (HF) study and a tolerability assessment of the device. The HF Study involved 110 participants (63 early AD patients, 32 care partners, and 15 healthcare professionals: HCPs) to assess the appropriate administration of lecanemab SC-AI. Overall, 95% (104/110) of participants successfully administered the maintenance dose. The Autoinjector Device Acceptability Study involved 126 participants (25 early AD patients, 50 care partners, and 51 HCPs), to evaluate the device's ease of use, convenience and feasibility of administration. As an interim outcome, over 95% of participants reported that the SC-AI is easy to administer. They were highly satisfied with it and had no concerns about administration, even at home. Furthermore, all patients responded that they welcomed the introduction of SC-AI. These studies and evaluations of lecanemab SC-AI have demonstrated that the investigational SC-AI offers efficacy and safety comparable to IV administration with the potential to reduce the incidence of infusion site adverse events. From the perspective of patients and care partners, benefits included the ability to use the device at home, shortening treatment time, and to continue treatment without having to worry about visiting an infusion center. From the perspective of HCPs, they reported that the device has the potential to provide a new option for patients who are benefiting from lecanemab to continue the treatment. The SC formulation has the potential to reduce medical preparation and administration time related to IV therapy. These factors suggest that the SC AI may play an important role in continuing treatment for early AD. This release is based on the content of the presentations given at AAIC, "Featured Research Session #4-13-FRS-C: Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's Disease," held at 9:00 AM on Wednesday, July 30, and also includes some content from the Developing Topics session held at 8:00 AM on Sunday, July 27, entitled "Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients." Eisai serves as the lead for lecanemab's development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. * Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.1 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD. 2 MEDIA CONTACTSEisai Co., Ltd. Public Relations Department TEL: +81 (0)3-3817-5120 Eisai Europe, Ltd. EMEA Communications Department +44 (0) 797 487 9419 Emea-comms@ Eisai Inc. (U.S.) Libby Holman +1-201-753-1945 Libby_Holman@ Biogen Inc. Madeleine Shin +1-781-464-3260 INVESTOR CONTACTSEisai Co., Ltd. Investor Relations Department TEL: +81 (0) 3-3817-5122 Biogen Inc. Tim Power + 1-781-464-2442 IR@ Notes to Editors 1. About lecanemab (generic name, brand name: LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells.2 It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction. Lecanemab has been approved in 46 countries and is under regulatory review in 11 countries. In January 2025, the supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S. After an 18 months initiation phase with once every two weeks of dosing, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks or continuing 10 mg/kg once every two weeks may be considered. Additionally, the U.S. Food and Drug Administration (FDA) accepted Eisai's Biologics License Application (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025. Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. 2. About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3. About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. 4. About Eisai Co., Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners. For more information about Eisai, please visit (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit and Eisai EMEA LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The company routinely posts information that may be important to investors on its website at Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. Biogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned "Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. References Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. View original content to download multimedia: SOURCE Eisai Inc.
Yahoo
a day ago
- Yahoo
Dental Imaging Market Worth US$4.69 billion by 2030 with 7.5% CAGR
DELRAY BEACH, Fla., July 30, 2025 /PRNewswire/ -- The global Dental Imaging Market, valued at US$3.08 billion in 2024 stood at US$3.26 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2030, culminating in a forecasted valuation of US$4.69 billion by the end of the period. The dental imaging market is experiencing growth due to ongoing innovations in imaging technologies that provide precise results. Several factors contribute to this market expansion, including the increasing number of dental professionals, a rising demand for aesthetic treatments, and a higher prevalence of dental caries and periodontal diseases that require effective diagnostic tools. Patients and dental professionals alike prefer early and accurate disease diagnosis, which further drives the demand for dental imaging. Additionally, there is a growing need for accurate and efficient diagnostic tools, such as intraoral cameras. This factor, along with the increasing affordability of imaging systems, has led to greater adoption of dental imaging technologies in dental hospitals worldwide. Download PDF Brochure: Browse in-depth TOC on "Dental Imaging Market" 150 - Tables45 - Figures250 - Pages By product, the dental imaging market has been divided into two main categories: extraoral and intraoral imaging systems. Among the extraoral imaging systems segment, panoramic imaging systems represented the largest share in 2024. This significant share is largely due to its extensive applications in general dentistry, implantology, endodontics, and periodontics, where it is used for initial patient assessments and to enhance accuracy in treatment planning. By application, the market has been segmented based on application into five main categories: implantology, endodontics, oral & maxillofacial surgery, orthodontics, and other applications. Among these segments, implantology represented the largest share in 2024. As people become more focused on aesthetics, the demand for implants is increasing. The placement of implants requires a detailed understanding of bone density, nerve pathways, and anatomical structures, which has led to a growing need for 3D imaging. Cone beam computed tomography (CBCT) is in high demand for implant planning, as it assists surgeons during surgery. By end user, the dental imaging market is segmented based on end users into three categories: dental clinics & hospitals, dental diagnostic centers, and dental academic & research institutes. In 2024, the dental clinics & hospitals segment held the largest market share. This dominance can be attributed to several factors, including the growing affordability of imaging systems, an increasing need for accurate and rapid diagnoses, and heightened awareness among patients. By geography, The Asia Pacific region is anticipated to experience the highest growth during the forecast period, mainly due to the increasing demand for dental imaging technology in countries such as China, India, Japan, and South Korea. As a result, many global companies are concentrating on enhancing their research and development capabilities as well as expanding their distribution networks in this region. In 2024, North America held the largest share of the dental imaging market, followed by Europe. Request Sample Pages : The prominent players in the dental imaging market include Envista Holdings Corporation (US), Planmeca Oy (Finland), ACTEON (UK), DENTSPLY SIRONA Inc. (US), Carestream Dental LLC (US), VATECH (South Korea), Owandy Radiology, Inc. (France), DÜRR DENTAL AG (Germany), Midmark Corporation (US), Genoray Co., Ltd. (South Korea), Asahi Roentgen Co., Ltd. (Japan), 3Shape (Denmark), PreXion, Inc. (US), Ningbo Runyes Medical Instrument Co. Ltd.(China), Cefla Medical Equipment (Italy), Apteryx Imaging (Canada), Yoshida Dental Mfg. Co., Ltd. (Japan), Align Technology Inc. (US), J. MORITA CORP (Japan), and FONA Srl (Italy). Envista Holdings Corporation (US): Envista Holdings Corporation (US) is a leader in the global dental imaging market. As a prominent global dental products company, Envista has a strong presence in dental imaging, primarily through its flagship brand, DEXIS. The company offers a comprehensive range of imaging solutions, including intraoral sensors, 3D CBCT systems, panoramic and cephalometric units, as well as AI-powered diagnostic software. To increase its share in the dental imaging market, Envista continuously focuses on product development and innovation. In February and May 2024, DEXIS launched the DEXIS Digital and DEXIS Ti2 intraoral scanners, demonstrating the company's commitment to frequent product advancements. DENTSPLY SIRONA (US) DENTSPLY SIRONA (US) held the second-leading position in the dental imaging market and is recognized as one of the top players in the industry, serving numerous sectors across a wide geographic area. Its emphasis on research and development (R&D) allows it to expand its product portfolio and diversify its offerings. In September 2024, the company introduced Primescan 2, a new product that enables users to scan directly to the cloud from any internet-connected device. VATECH (South Korea) VATECH (South Korea) is a leader in dental imaging technologies, specializing in a comprehensive range of X-ray systems, including intraoral and panoramic units, as well as high-end CBCT scanners and complementary software solutions. In 2024, the company intensified its focus on AI innovation, introducing advanced features such as 3D CBCT segmentation for teeth, roots, and nerves, along with image enhancement capabilities that include noise reduction and resolution improvements. For more information, Inquire Now! Related Reports: Dental Equipment Market Dental Implants and Prosthetics Market Dental Bone Graft Substitute Market Dental Digital X-ray Market Dental Bone Graft Substitute Market Get access to the latest updates on Dental Imaging Companies and Dental Imaging Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
